Skip to content
Clinical Trials – home
Research site

Ospedale S G Moscati

Italy Via Per Martina Franca, 74010 Statte, Italy

  • 14 trials recruiting
  • Colorectal cancer metastatic · Chronic obstructive pulmonary disease · Non-small cell lung cancer
  • Adult patients

About Specializations

Ospedale S G Moscati in Statte, Italy specialises in clinical trials of conditions such as Colorectal cancer metastatic, Chronic obstructive pulmonary disease, Non-small cell lung cancer, Lung disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology: Lung Cancer

The medical center is at the forefront of research in Limited-Stage Small-Cell Lung Cancer (LS SCLC), focusing on innovative treatments post-chemoradiotherapy. The center's work in this area aims to enhance progression-free survival through advanced therapeutic options.

  • Small-Cell Lung Cancer
  • Post-Chemoradiotherapy Treatments
  • Progression-Free Survival

By integrating cutting-edge research with clinical practice, the center is pioneering new pathways in lung cancer treatment, offering hope for improved patient outcomes.

Oncology: Colorectal Cancer

Specializing in metastatic colorectal cancer, the center explores the efficacy of various treatment regimens, including intermittent and continuous therapies. The focus is on improving safety, tolerability, and quality of life for patients with RAS/B-RAF wild-type tumors.

  • Intermittent vs. Continuous Treatment
  • Biomarker-Driven Therapies
  • Quality of Life Improvements

The center's research contributes significantly to understanding resistance mechanisms and optimizing therapeutic strategies for colorectal cancer.

Oncology: Acute Lymphoblastic Leukemia

In the realm of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, the center is investigating chemo-free strategies that combine targeted therapies with monoclonal antibodies. This approach aims to improve event-free survival and reduce toxicity.

  • Chemo-Free Strategies
  • Targeted Therapy Combinations
  • Event-Free Survival

Through innovative research, the center is redefining treatment paradigms, offering new hope for adult patients with this challenging leukemia subtype.

Oncology: Ovarian and Related Cancers

The center is advancing research in BRCA wild-type advanced ovarian, fallopian tube, and primitive peritoneal cancer through maintenance therapy studies. The focus is on evaluating the efficacy of Olaparib and its impact on progression-free survival.

  • Maintenance Therapy
  • Olaparib Efficacy
  • Prognostic Biomarkers

By exploring the biological characteristics of tumors, the center aims to tailor treatments that enhance patient outcomes in these complex cancer types.

Oncology: Non-Small-Cell Lung Cancer

Focusing on advanced non-small-cell lung cancer, the center is evaluating combination therapies to improve overall survival in patients with high PD-L1 expression. This research is pivotal in optimizing first-line treatment strategies.

  • Combination Therapies
  • PD-L1 High Expression
  • Overall Survival Improvement

The center's work in this area is crucial for developing personalized treatment plans that address the unique needs of lung cancer patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Per Martina Franca74010 StatteItaly
Recruiting now
14 trials
Conditions studied
16

More sites in StatteItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

22 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nvl-655
  • Sponsor:Nuvalent Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Ricerca Traslazionale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.